Environmental demands, the evolution of care models, new delivery technologies and AI tools are influencing how medtechs must approach innovation.
April 2024 sees another milestone in the fast-developing environmental compliance agenda for medtech and health care products suppliers. That is when the UK’s National Health Service ratchets up its Net Zero Commitment (NZC) requirements on suppliers, bringing into scope procurement contracts worth under £5m ($6m).
Suppliers in this bracket will have to demonstrate a commitment to net zero and comply with Carbon Reduction Plan demands....
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
The seventh annual edition of In Vivo’s Rising Leaders features entrepreneurs, academics, lawyers, regulators and innovators from around the globe, representing the forefront of creativity in health care.
